Adsorptive therapy as a modificator for tumor-host interaction
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-3.13576Keywords:
cisplatin, enterosorption, HemoSorbent Granulated Deliganding, hemosorption, paraneoplastic syndrome, radio- and chemotherapyAbstract
Summary. The potential of one of the adsorption methods, enterosorption (ES), using the new generation of carbon adsorbents to correct the negative manifestations of tumor-host interaction in the framework of paraneoplastic syndrome (PNS) as well as systemic toxicity of chemo- and radiation therapy, is discussed. The ES influence on the development of PNS was demonstrated in C57/BL6 mice with transplanted Lewis lung carcinoma. Two-week administration of carbon enterosorbents resulted in a significant suppression of metastasis and correction of tumor-related anemia, activation of granulocytic line in the bone marrow with nearly 3-fold enhancement of its mitotic activity. ES exerted a positive influence on the structural-morphologic indexes and regenerative potential of kidneys and liver, mitigated manifestations of oxidative stress, decreased the level of endogenous intoxication, increased resistance of erythrocyte membranes and decreased ligand loading of blood plasma transport proteins. The effect of ES on anticancer activity and toxic reactions of cisplatin (CP) was evaluated in Guerin carcinoma-bearing rats. ES reduced significantly creatinine and other kidney biochemical indexes elevated in the blood plasma of rats after CP treatment. ES attenuated dystrophic changes in the histological structure of internal organs (kidney, liver, spleen), caused by tumor growth and significantly aggravated under the influence of CP. Such changes were specially traced in the kidneys and well reflect the nephroprotective potential of ES. In rats irradiated with X-ray in sublethal dose, highly activated granulated carbonic enterosorbents facilitated the restoration of white blood cells and lymphocyte count. The results obtained confirm the insights of academician R.E. Kavetsky predicting the future of adsorptive detoxification with activated carbons in the treatment of cancer patients.
References
Kavetsky RE. Host and Tumor Interaction. Kyiv: Naukova Dumka, 1977; 234 p. (in Russian).
Nikolaev VG, Sarnatskaya VV, Bardakhivskaya KI, et al. New approaches to sorption therapy of kidney pathologies. Efferent Therapy 2003; 9: 26–39 (in Russian).
Sarnatskaya VV, Yushko LA, Nikolaev AV, et al. New approaches to the removal of protein-bound toxins from blood plasma of uremic patients. Artif Cells Blood Substit Immobil Biotechnol 2007; 35: 287–309.
Nikolaev VG. The Method of Hemocarboperfusion in Experiment and in Clinics. Kyiv: Naukova Dumka, 1984; 360 p. (in Russian).
Nikolaev VG, Sakhno LA, Snezhkova EA, et al. Сarbon adsorbents in oncology: achievements and perspectives. Exp Oncol 2011; 33: 2–8.
Nikolaev VG, Mikhalovsky SV, Gurina NM, et al. Carbon enterosorbents and mechanism of their action. Efferent Therapy 2005; 11: 3–17 (in Russian).
Sarnatskaya VV, Sidorenko AS, Klymchuk DA, et al. Optimization of physico-chemical properties of carbon enterosorbents and evaluation of their sorption activity for use in the treatment of paraneoplastic syndrome and other endogenous intoxications in cancer patients. Exp Oncol 2013; 35: 83–8.
Sarnatskaya VV, Nikolaev VG, Paziuk LM, et al. Enterosorption-induced mitigation of paraneoplastic syndrome manifestations associated with tumor angiogenesis. Exp Oncol 2015; 37: 255–61.
Sarnatskaya VV, Sakhno LA, Paziuk LM, et al. Highly activated carbon enterosorbent mediates the suppression of paraneoplastic syndrome associated with Lewis lung carcinoma in mice. Exp Oncol 2018; 40: 33–41.
Xing C, Liang B, Wu J, et al. Prognostic significance of leukopenia during the induction phase in adult B cell acute lymphoblastic leukemia. Cancer Manag Res 2018; 10: 625–35.
Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005; 63: 1427–31.
Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011; 47: 8–32.
Nikolaev VG, Pinchuk LB, Umansky MA, et al. Early experimental studies on hemoperfusion as a treatment modality for acute radiation disease. J Artif Organs 1993; 17: 362–5.
Shevchuk OO, Snezhkova EA, Bilous AG, et al. Sorption detoxification as an addition to conventional therapy of acute radiation sickness and iatrogenic leukopenia. In: Leucocyte Biology. Ed. Intechopen, 2019. Retrieved from https://www.intechopen.com/online-first/sorption-detoxification-as-an-addition-to-conventional-therapy-of-acute-radiation-sickness-and-iatro.
Kandemir FM, Yildirim S, Caglayan C, et al. Protective effects of zingerone on cisplatin-induced nephrotoxicity in female rats. Environ Sci Pollut Res Int 2019. doi: 10.1007/s11356-019-05505-3.
Sakul A, Ozansoy M, Elibol B, et al. Squalene attenuates the oxidative stress and activates AKT/mTOR pathway against cisplatin-induced kidney damage in mice. Turk J Biol 2019; 43:179–88.
Sakhno LA, Yurchenko OV, Maslenniy VN. Enterosorption as a method to decrease the systemic toxicity of cisplatin. Exp Oncol 2013; 35: 45–52.
Muravskaya GV, Nikolaev VG, Sergeev VP, et al. Enterosorption in oncotherapy. Biomater Artif Cells Immobilization Biotechnol 1991; 19: 167–74.
Ponomarova OV, Pivnyuk VM, Nosko MM, et al. Prophylaxis by coal enterosorbent of acute and extended emethogenic toxicity in cancer patient chemotherapy. Onkologiya 2008; 3: 370–3 (in Ukrainian).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
